Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
about
Intelligent design: combination therapy with oncolytic virusesOncolytic virotherapy using herpes simplex virus: how far have we come?IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2.Molecular and functional imaging technology for the development of efficient treatment strategies for gliomas.B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cellsAltered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysisEvaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant.Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersHSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applicationsDevelopment of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer.Oncolytic herpes viral therapy is effective in the treatment of hepatocellular carcinoma cell lines.The herpes simplex virus type 1 UL3 transcript starts within the UL3 open reading frame and encodes a 224-amino-acid proteinRegulation of herpes simplex virus gamma(1)34.5 expression and oncolysis of diffuse liver metastases by Myb34.5.Directing systemic oncolytic viral delivery to tumors via carrier cellsEngineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review.Design and application of oncolytic HSV vectors for glioblastoma therapy.Oncolytic herpes viruses as a potential mechanism for cancer therapy.Gene transfer and genome-wide insertional mutagenesis by retroviral transduction in fish stem cells.ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.Oncolytic viral therapies - the clinical experience.Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity.Herpes simplex virus 1 (HSV-1) for cancer treatment.Herpes simplex virus type-1(HSV-1) oncolytic and highly fusogenic mutants carrying the NV1020 genomic deletion effectively inhibit primary and metastatic tumors in mice.Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with ProdrugsSpread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.HSV Recombinant Vectors for Gene Therapy.Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.Identification and functional characterization of glioma-specific promoters and their application in suicide gene therapy.Ultrastructural analysis of ICP34.5- herpes simplex virus 1 replication in mouse brain cells in vivo.Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.Enhanced therapeutic efficacy of G207 for the treatment of glioma through Musashi1 promoter retargeting of gamma34.5-mediated virulence.
P2860
Q24628227-A7C39761-C872-4ACE-A1CC-38BD113AA6B3Q26862461-777CD1C6-065E-4822-9F52-15A03459684CQ30355682-57CD63AB-9D3B-4C00-AC64-1DC0C0725089Q30501507-52C95532-E554-4280-9B0B-9C78D0C6DCD7Q30775012-B7A3C130-5F3D-47CF-8E3F-7831F46093A1Q33649894-DF9EE993-C4E3-4AF4-9C89-11AD39FD6707Q33675567-2AF57378-FC08-4F74-8505-60BE5C195CA6Q33720628-B3998196-DEA5-4E1B-9DC8-87D552A4279DQ33804845-958B66E5-71DB-47FA-B4C6-B8D05F2B313DQ33904270-45D1D720-BC45-4DD9-83EB-8D41A17FB4C9Q33985663-73CDF939-46EC-469F-A155-D85EFCFC3CDAQ33995752-AFEAC6C9-76E4-4073-9099-94602AF1DE66Q34046125-162361D8-5E71-4C4E-B107-F03BEFE09C0AQ34375025-F44E18CD-C134-49BE-95C8-603EF77F4A42Q34557399-896BC80C-4C6F-4885-A980-BFCD031E3107Q34649460-98923331-F0D2-437A-8903-894003544FCDQ34790267-61A3189D-7700-49BD-918E-FBFD7306BCEBQ35029126-A8C51DC9-B760-4FD0-888A-47697376B4FEQ35051285-F1F60E47-9C67-4E8D-9596-964CB6B36883Q35116166-BD4F24A6-31C6-47D8-8BD5-777892B78261Q35126267-D2E99B54-493C-4110-A902-B1C33AD6ED11Q35559877-F7A52299-C412-4F9E-B0E4-0F5E9BDEA766Q35613495-6B1308C4-E2B3-41F0-B479-6D25744B772EQ35647626-C5FC49FF-1BBA-4C00-9AAB-4A7A3714A32EQ35699072-4D12CCB1-3720-4889-B78F-DCCEDD0D57AEQ35943736-3837B7D1-F985-4CF8-996C-783CE06FB17DQ36318160-E6B1346B-5126-4BBE-8E36-5ACC7E8DD34EQ36318202-9525D96D-EE00-43FF-84AE-55DD1F652049Q36438502-BD200EA7-C01A-47E0-9478-046BD6D4FFADQ36444443-F93DAFEF-F66E-4BE7-BCF4-5740B69CE081Q36755502-BA806FE4-7488-4160-B2F4-1AB06484234FQ36849213-DFA33EC6-64AE-48EA-A2BD-A15F33D8A65AQ37138701-1C4F09C2-7145-4784-B8AD-5920AD6CE27CQ37596491-8084DD12-C503-4DF5-9F81-3F3CFF80EF74Q37787777-13847A2C-DB89-45C4-B874-114B429BBDC7Q38735164-BB550AE6-74F8-4927-A5D1-60812E6D5AF2Q39586718-BCD00909-8747-4A9C-9B45-292282F0018BQ39848419-F272AEB1-A84A-4D9A-925C-8F4A743C0259Q40327891-FCA0F999-0948-4D47-A9D0-ABB5021B171CQ40373406-9BC75A17-4AD4-409E-A1C3-A8F9AB57B02B
P2860
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Therapeutic efficiency and saf ...... for brain tumor gene therapy.
@en
Therapeutic efficiency and saf ...... for brain tumor gene therapy.
@nl
type
label
Therapeutic efficiency and saf ...... for brain tumor gene therapy.
@en
Therapeutic efficiency and saf ...... for brain tumor gene therapy.
@nl
prefLabel
Therapeutic efficiency and saf ...... for brain tumor gene therapy.
@en
Therapeutic efficiency and saf ...... for brain tumor gene therapy.
@nl
P2093
P1433
P1476
Therapeutic efficiency and saf ...... r for brain tumor gene therapy
@en
P2093
Barnett FH
Breakefield XO
Chiocca EA
Herrlinger U
Sena-Esteves M
P304
P356
10.1089/HUM.1997.8.17-2057
P577
1997-11-01T00:00:00Z